Assessing Oddity Tech (ODD) Valuation After Weak Earnings And Steep Revenue Guidance Cut

Advertisement

Why Oddity Tech’s latest earnings and outlook matter for investors

Oddity Tech (ODD) recently reported a swing from profit to net loss alongside lower first quarter sales, and guided to a 25% to 30% year-over-year net revenue decline for the second quarter.

This combination of weaker recent results and cautious guidance has sharpened investor focus on Oddity Tech’s growth profile, profitability path, and how the stock’s sharp pullback over the past month and past 3 months fits into the story.

See our latest analysis for Oddity Tech.

The latest guidance for a 25% to 30% year-over-year net revenue decline in the second quarter appears to have weighed heavily on sentiment. The stock’s 30-day share price return is down 32.87% and its 1-year total shareholder return is down 86.73%, pointing to fading momentum despite a recent 1-day share price gain of 4.17% to US$10.25.

If this sharp move has you reassessing where growth and risk are being repriced, it could be a useful moment to scan 20 top founder-led companies

With guidance pointing to weaker near term revenue and the stock down sharply over the past year, the key question is whether Oddity Tech is now trading below its fundamentals or if the share price already reflects slower growth ahead.

Most Popular Narrative: 36.9% Undervalued

Oddity Tech’s most followed narrative pegs fair value at $16.25 a share versus the last close at $10.25, framing the recent selloff as a potential mispricing to interrogate rather than a verdict.

Upcoming new market launches in medical-grade dermatology and telehealth with Brand 3, leveraging Oddity's large, data-rich user base, AI-driven personalization, and proprietary molecules, introduce an entirely new vertical and customer segment, likely providing incremental and diversified revenue streams that are not factored into near-term outlooks.

Read the complete narrative.

Want to see how steady top line assumptions, firmer margins, and a future earnings multiple are stitched together to reach that fair value? The, often surprising, mix of growth expectations, profitability shifts, and required valuation re rating sits at the heart of this narrative and is worth checking against your own view.

Result: Fair Value of $16.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, higher customer acquisition costs and the class action lawsuit around advertising disclosures could pressure margins and sentiment, which may challenge the current undervalued narrative.

Find out about the key risks to this Oddity Tech narrative.

Another angle on what the current price might be saying

Oddity Tech’s own checks send a mixed message. On one hand, the stock trades on a P/E of 11.3x, which looks cheaper than the global Personal Products industry at 18.1x. On the other hand, it sits above the peer average of 8.8x and slightly above a fair ratio of 10.9x, which suggests less room for error if earnings or sentiment weaken further.

For investors weighing whether that gap points to opportunity or valuation risk, the detailed multiple breakdown is worth a closer look, particularly alongside See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:ODD P/E Ratio as at Jun 2026
NasdaqGM:ODD P/E Ratio as at Jun 2026

Next Steps

If this mix of concern and optimism feels familiar, it is a good time to review the data for yourself and decide where you stand, starting with 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Oddity Tech has sharpened your thinking, do not stop there. Broaden your watchlist now so you are not late to the next opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:ODD

Oddity Tech

Operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States, Israel, and internationally.

Moderate risk and slightly overvalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0